Oncology
Pushing the Boundaries for People with HER3-Positive Tumors
The human epidermal growth factor 3 (HER3) protein is over-expressed in many solid tumor cancers, including breast, ovarian, lung, gastrointestinal, colorectal, melanoma and cervical cancers. Tumors that are HER3-positive are associated with poor prognosis and resistance to certain types of therapies, making HER3 an important target for new treatments.
Existing cancer therapies have shown limited clinical efficacy in HER3-expressing tumors and patients urgently need new treatment options.
Recent studies suggest that the class of drugs known as antibody-drug conjugates (ADCs) offer a promising new option for treating HER3-positive cancers. When designed to target the HER3 protein, these compounds can deliver a highly toxic payload to kill tumor cells.
Endeavor’s Disruptive Approach
Endeavor BioMedicines is developing ENV-501, an optimized next-generation anti-HER3 ADC engineered to minimize the limitations associated with earlier generations of HER3 ADCs. ENV-501’s design has the potential to treat multiple tumor types that overexpress HER3.
